药物基因组学与心律失常疾病的治疗

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (11): 1315-1320.

• 综述与讲座 • 上一篇

药物基因组学与心律失常疾病的治疗

申音^1,2, 邓婕^1,2, 宋洪涛¹

¹南京军区福州总医院药学科,福建 350025,福州;
²沈阳药科大学药学院,沈阳 110016,辽宁

收稿日期:2010-10-19 修回日期:2010-11-12 出版日期:2010-11-26 发布日期:2020-09-16
作者简介:申音,女,硕士研究生,研究方向:临床药学。Tel: 18750194532 E-mail: shenyinemail@126.com;宋洪涛,男,博士,主任药师,硕士生导师,研究方向:药剂学,临床药学。Tel: 0591-22859459 E-mail: sohoto@vip.sohu.com

Pharmacogenomics and therapy in arrhythmic disease

SHEN Ying^1,2, DENG Jie^1,2, SONG Hong-tao¹

¹Department of Pharmacy, Fuzhou General Hospital of Nanjing Military Region, Fujian 350025, Fuzhou, China;
²College of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, China

Received:2010-10-19 Revised:2010-11-12 Online:2010-11-26 Published:2020-09-16

摘要/Abstract

摘要： 抗心律失常药物的治疗剂量和中毒剂量非常接近,而个体的差异易引起药物的不良反应。为此研究抗心律失常药物的药物基因组学来正确地引导药物的使用,以期达到理想的治疗效果并减少毒副作用。本文就近年来抗心律失常药物基因组学的研究进展作一综述。

关键词: 药物基因组学, 抗心律失常药物, 基因多态性, 药物代谢酶

Abstract: Therapeutic dose and toxic dose about antiarrhythmic drugs are extremely near, and the individual difference is easy to induce drug adverse reaction. Studies on pharmacogenomics of antiarrhythmic drugs have correctly conducted the use of drugs in order to achieve desirable treatment and effectiveness and reduce side effects. This article presents an overview of the current research progress of pharmacogenomics of antiarrhythmic drugs.

Key words: Pharmacogenomics, Antiarrhythmic drugs, Genomic polymorphism, Drug metabolizing enzyme

中图分类号:

R969

申音, 邓婕, 宋洪涛. 药物基因组学与心律失常疾病的治疗[J]. 中国临床药理学与治疗学, 2010, 15(11): 1315-1320.

SHEN Ying, DENG Jie, SONG Hong-tao. Pharmacogenomics and therapy in arrhythmic disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(11): 1315-1320.

参考文献

[1] Ovaska H,Ludman A,Spencer EP,et al.Propafenone poisoning-a case report with plasma propafenone concentrations[J]. J Med Toxicol, 2010, 6(1):37-40.
[2] Magnus IS, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects[J]. Pharmacol Ther, 2007, 116(3): 496-526.
[3] Taguchi M, Nozawa T, Kameyama T, et al. Effect of CYP2D6^*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients[J]. Eur J Clin Pharmacol, 2003, 59(5/6): 385-388.
[4] Sharp CF, Gardiner SJ, Jensen BP, et al. CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure CYP2D6, metoprolol and heart failure[J]. Pharmacogenomics J, 2009, 9(3): 175-184.
[5] Chen B, Cai WM. Influence of CYP2D6^*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects[J]. Acta Pharmacol Sin, 2003, 24(12): 1277-1280.
[6] 李拴美, 刘端, 朱娟莉, 等. 体外研究人细胞色素P450 3A4等位基因多态性对药物代谢和药物相互作用的影响[J]. 中国医药生物技术, 2009, 4(3): 177-183.
[7] Sheffield LJ, Phillimore HE. CYP3A4 is the most abundant enzyme and is associated with metabolism of about 50% of drugs in clinical use[J]. Clin Biochem Rev, 2009, 30(2): 55-65.
[8] Cheng JWM, Frishman WH, Aronow WS. Updates on Cytochrome P450-Mediated Cardiovascular Drug Interactions[J]. Am J Ther, 2009, 16(2): 155-163.
[9] Xu P, Jiang ZP, Zhang BK, et al. Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers[J]. Pharmacology, 2008, 82(3): 221-227.
[10] McBride BF, Yang T, Roden DM. Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG[J].Pharmacogenomics J, 2009, 9(3): 194-201.
[11] Ni LN, Li JY, Miao KR, et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia[J]. Med Oncol,2010 Mar 4. [Epub ahead of print].
[12] Sakata T, Anzai N, Shin HJ, et al. Novel single nucleotide polymorphisms of organic cation transporter 1(SLC22A1) affecting transport functions[J]. Biochem Biophys Res Comman, 2004, 313(3): 789-793.
[13] Zill P, Baghai TC, Engel R, et al. Beta-1-adrenergic receptor gene in major depression: influence on antidepressant treatment response[J]. Am J Med Genet B Neuropsychiatr Genet, 2003, l20(1): 85-89.
[14] Xie HC, Dishy V, Sofowora G, et al. Arg389Gly betal-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo[J]. Pharmacogenetics, 2001, 11(3): 191-197.
[15] Johnson JA, Zineh I, Puckett BJ, et al. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol[J]. Clin Pharmacol Ther, 2003, 74(1): 44-52.
[16] Liu J, Liu ZQ, Tan ZR, et al. Arg389Gly polymorphism of betaladrenergic receptor is associated with the cardiovacular response to metoprolol[J]. Clin Pharmacol Ther, 2003, 74(4): 372-379.
[17] 李为民, 甘润韬. β₁肾上腺素受体基因多态性与心血管疾病的研究进展[J]. 心肺血管病杂志, 2007, 26(3):185-187.
[18] Metra M, Covolo L, Pezzali N, et al. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure[J]. Cardiovasc Drugs Ther, 2010, 24(1): 49-60.
[19] Allen N, Chen C, Agrawal R, et al. β₁ and β₂ Adrenergic receptor polymorphisms: their impact on cardiovascular physiology, disease states, and response to therapeutic agents [J]. J Crit Care, 2007, 26(1): 2-9.
[20] Lanfear DE, Jones PG, Marsh S, et al. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome[J]. JAMA, 2005, 294(12): 1526-1533.
[21] Lizotte E, Junttila MJ, Dube MP, et al. Genetic Modulation of Brugada Syndrome by a Common Polymorphism[J]. J Cardiovasc Electrophysiol, 2009, 20(10): 1137-1141.
[22] 李绪勇, 李晓艳, 蒋学俊, 等. 普罗帕酮对HERG钾通道孔胞膜外侧氨基酸突变前后的作用[J]. 心血管康复医学杂志, 2010, 19(1): 49-53.
[23] Gaikovitch EA, Cascorbi I, Mrozikiewiez PM, el a1. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of Pglycoprotein in a Russian population[J]. Eur J Clin Pharmacol, 2003, 59(4): 303-331.

药物基因组学与心律失常疾病的治疗

Pharmacogenomics and therapy in arrhythmic disease

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李坤, 李璐璐, 李楠楠, 胡卫红, 周建超. 成人肾移植术后血糖控制和CYP3A5基因多态性对他克莫司谷浓度的影响[J]. 中国临床药理学与治疗学, 2023, 28(7): 767-774.
[2]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[3]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[4]	张志英, 靳秀红, 张小宁, 张向峰, 罗青林, 张松林. TBX21和ADCY9多态性在儿童哮喘发生发展中的临床研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 407-412.
[5]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[6]	王爽, 刘嘉, 张月丽. POR*28基因多态性与中国肾移植患者他克莫司稳定剂量的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(9): 991-997.
[7]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[8]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[9]	武元竹, 刘俊, 杨魁, 彭静, 栾家杰, 韦俊, 张大发, 宋帅, 袁小龙, 王中方, 张年宝, 解丹, 姜鹏, 范洁. 安徽地区汉族人群CYP2C9*3和VKORC1-1639G>A基因多态性分布及对华法林稳定剂量的影响[J]. 中国临床药理学与治疗学, 2022, 27(6): 652-659.
[10]	孙媛媛, 邓锟红, 王思懿, 况赟, 邹婵, 郭成贤, 何庆南, 刘和林, 阳国平. 个体化用药基因电子身份应用程序的设计与实现[J]. 中国临床药理学与治疗学, 2022, 27(3): 274-280.
[11]	陈佳音, 王丽, 王立军, 童刚领, 马洁, 陈西敬, 卢杨. 有机阳离子转运体基因多态性与奥沙利铂毒性及疗效的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(2): 171-177.
[12]	周晗, 刘晓东. 生理药代动力学模型在创新药物评价中应用及其若干问题的思考[J]. 中国临床药理学与治疗学, 2021, 26(8): 889-913.
[13]	张远金, 黄盛博, 刘洁, 王昕. 药物代谢创新模型：基因编辑大鼠和小肠3D类器官[J]. 中国临床药理学与治疗学, 2021, 26(8): 914-922.
[14]	周敏敏, 余露, 韩超, 顾达民, 雷道赟. 人类胆固醇酯转移蛋白rs5882基因多态性与围术期神经认知功能紊乱的相关性[J]. 中国临床药理学与治疗学, 2021, 26(7): 768-774.
[15]	王春玲, 周仁精, 冯瑞, 吴燕能. 脂联素45 T/G基因多态性对利拉鲁肽治疗2型糖尿病患者的临床疗效[J]. 中国临床药理学与治疗学, 2021, 26(3): 312-317.